Kinfo
BridgeBio Pharma Inc. logo

BridgeBio Pharma Inc.

BBIONASDAQHealthcare·US · USD
$76.80
-0.56 (-0.72%)
Prices as of November 17, 2026 · market closed

Price

Key statistics

Valuation
Market cap14.96B USD
Enterprise value18.04B USD
Trailing P/E-20.31
Forward P/E-283.02
PEG ratio1.13
Price / sales15.94
Price / book-6.00
Profitability
Gross margin93.83%
Operating margin-37.34%
Profit margin-59.84%
Return on assets-13.97%
Return on equity34.91%
Income (TTM)
Revenue945.54M USD
Gross profit892.00M USD
EBITDA-348.36M USD
Net income-592.12M USD
Diluted EPS-$3.03
Rev. growth (YoY)192.60%
Balance sheet
Total cash1.54B USD
Total debt3.38B USD
Debt / equity-1.35
Current ratio2.09
Book value / share-$13.29
Cash flow (TTM)
Operating cash flow-368.97M USD
Levered free cash flow-287.13M USD
Shares & price
Shares outstanding195.28M
Float163.00M
Held by institutions98.95%
Beta0.94
50-day MA$69.98
200-day MA$72.69
52-week high$93.42
52-week low$62.50
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-10-29-0.56-0.42+25.00%2026-08-10-0.58-0.78−34.48%2026-05-07-0.62-0.84−35.48%2026-02-24-0.62-0.94−51.61%2025-12-17-0.360.10+127.78%
About BridgeBio Pharma Inc.

BridgeBio Pharma Inc. is a commercial-stage biopharmaceutical company focused on developing medicines for genetic conditions. BridgeBio Pharma Inc. discovers, develops, tests, and delivers therapies aimed at patients with rare and inherited diseases, with programs spanning cardiology, endocrinology, muscle disease, gene therapy, and selected oncology. The company’s current portfolio includes approved medicines such as Attruby for transthyretin amyloid cardiomyopathy and Nulibry for a rare metabolic disorder, alongside a pipeline of investigational treatments for additional genetic disorders. BridgeBio Pharma Inc. works with academic and industry partners to advance precision medicines and bring targeted treatment options to underserved patient groups. Headquartered in Palo Alto, California, BridgeBio Pharma Inc. plays a significant role in the genetic-disease biopharmaceutical market through its mix of commercial products and late-stage development programs.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Neil Kumar Ph.D.
Employees
1,081
Headquarters
Palo Alto, CA, United States

Frequently asked questions about BridgeBio Pharma Inc.